Spyre Therapeutics, Inc. SYRE Business Segments — Compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s business segments — compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s business segments — compensation?
- Spyre Therapeutics, Inc. (SYRE) reported business segments — compensation of $11.44M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s business segments — compensation changed year-over-year?
- Spyre Therapeutics, Inc.'s business segments — compensation increased by 63.7% year-over-year, from $6.99M to $11.44M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s business segments — compensation?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s business segments — compensation has grown at a 10.5% compound annual growth rate (CAGR), from $25.78M to $34.8M.
- What does business segments — compensation mean?
- Represents the total cash-based salary, wages, and benefits paid to employees within the primary business segment. This metric reflects the core human capital investment required to sustain operational and research activities.